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Summary.-Mice bearing a methylcholanthrene-induced tumour were tested for
their cell-mediated reactivity to the experimental allergic encephalomyelitis (EAE)
peptide of human myelin basic protein (MBP) in the leucocyte adherence inhibition
(LAI) test. Tested over a range of peptide concentrations, peritoneal cells (PC)
from tumour-bearing mice exhibited optimal adherence inhibition at 640 ng/ml;
PC from normal and parasite-infected mice were unreactive. The EAE peptide also
stimulated PC from tumour-bearing mice in the E-rosette augmentation (ERA)
test and in the macrophage migration inhibition (MMI) test. MMI appeared to be
the most sensitive assay, in that significant reaction at peptide concentrations well
below those giving significant LAI and ERA. LAI reactivity to the peptide was detec-
ted 5 days after tumour transplantation, and continued to be detectable even with
very large tumours. In vitro assays were confirmed by demonstration of EAE peptide
recognition in vivo, in tumour-bearing and tumour-excised mice, using the delayed-
type hypersensitivity reaction. The present experiments demonstrate an antigenic
determinant in murine tumours, similar to the well-characterized EAE peptide
of human MBP, and establish an animal model for study and characterization of
common tumour-associated antigens.
SINCE FIELD & CASPARY (1970) made the
surprising discovery that cancer patients'
lymphocytesreactedimmunologicallywith
myelin basic protein (MBP), and later
showed (Caspary & Field, 1971) that
the phenomenon was due to a common
tumour antigen, progress in this area has
been erratic. Although the basic observa-
tion has been confirmed repeatedly with
a variety of techniques, practical applica-
tions in human cancer are still doubtful
and the nature of the proposed common
antigen is obscure.
Most of the observations have been
made with the macrophage electrophoretic
mobility (MEM) technique, either as
described by Field & Caspary (1970)
or modified in various ways (Pritchard
et al., 1973; Dyson & Corbett, 1978).
It has been used to demonstrate lympho-
cyte reactivity in cancer, not only to
MBP itself (Caspary & Field, 1971;
Rawlins et al., 1976; Chiu et al., 1977)
but also to crude and partially purified
acid extracts of tumour tissues and cells
(Dickinson et al., 1973, 1974, 1980;
Carnegie et al., 1973; Shaw et al., 1976).
The common antigen of these extracts
has been named cancer basic protein
(CaBP) because of properties analogous
to MBP (Dickinson & Caspary, 1973).
Host reactivity to CaBP in human cancer
has also been detected by changes in the
structuredness of cytoplasmic matrix
(SCM) of lymphocytes (Cercek & Cercek,
1977). Both the MEM and SCM assays
have nevertheless generated much con-
troversy because of their technical de-
mands (Bagshawe, 1977).
Other techniques have confirmed that
lymphocyte sensitization to MBP in
cancer is a reality. Thus, extensive
studies with macrophage migration inhibi-
tion (MMI) revealed that most cancerCMI TO ENCEPHALITOGENIC PEPTIDE
patients reacted with MBP (also called
encephalitogenic factor, EF) (Flavell &
Potter, 1978; Flavell et al., 1978a; Howell
et al., 1980) and that lymphocytes of
tumour-bearing hamsters and rats were
sensitized (Flavell et al., 1978b). Leucocyte
adherence inhibition (LAI) also demon-
strated reactivity of lymphocytes to
MBP in human cancer (Schimke &
Ambrosius, 1981).
In contrast to the successful investiga-
tions on the structure of MBP and its
relationship to experimental allergic ence-
phalomyelitis (EAE) oflaboratory animals
(reviewed by Hashim, 1978), knowledge
concerning CaBP and its role in tumour
immunity is incomplete. The molecular
region of human MBP containing the
encephalitogenic determinant for guinea-
pigs has been isolated, characterized and
synthesized (Eylar et al., 1970); it is a
tryptophan-containing nonapeptide that
induces EAE in guinea-pigs but not in
rats or monkeys. This EAE peptide was
reported to be reactive in MEM with
cancer-patients' lymphocytes (Field et al.,
1971; Shaw et al., 1976) suggesting that
the cross-reactivity with MBP might
depend on a similar peptide determinant
in CaBP. Attempts to fractionate and
characterize immunologically active frag-
ments of human CaBP have so far been
only partially successful (Dickinson et al.,
1980).
Advances in the study of CaBP seem
to have been retarded by the limitations
of the laboratory techniques and the lack
ofa suitable animal model. The techniques
available are tedious and unreliable,
and human cancer patients are highly
variable. A report on the reactivity of
tumour-bearing mice with MBP in the
MEM assay (Pasternak et al., 1976)
suggested that the cross-reactivity of
MBP extended to these animals also,
and that they might be suitable for
establishing techniques leading finally
to applications in man. In our laboratory,
the LAI assay has been used extensively
with murine andhumantumours (Halliday
& Miller, 1972; Halliday et al., 1974a, b,
1977; Halliday, 1979; Koppi & Halliday,
1981). It was therefore decided to test
the reactivity of the EAE peptide in
experimental animal tumours, using LAI
and other confirmatory techniques. It
was hoped that this would lead to a better
understanding of the common antigenic
determinants oftumours.
MATERIALS AND METHODS
Animals.-Inbred CBA mice from the
Central Animal Breeding House, University
of Queensland, were used when 2-5 months
old, and were kept under conventional
animal-house conditions.
Nematospiroides dubius infection.-Mice
for one experiment were kindly supplied by
Dr C. Dobson, Department of Parasitology,
University ofQueensland. They were infected
orally with 100 infective N. dubius larvae at
4 weekly intervals (Dobson & Owen, 1977)
and were used 4 weeks after the last infection.
Tumour.-A fibrosarcoma (MCA-2) pre-
viously induced in a CBA mouse with 3-
methylcholanthrene was serially transplanted
by s.c. inoculation (Maluish & Halliday, 1975).
It was in the 16-18th transplant generation
at the time of this study. Tumour size was
determined by measuring the two greatest
opposing diameters after removal from the
animal. The transplanted pieces were
,05 mm in diameter.
Tumour extract.-Extraction with phos-
phate-buffered saline has been described
previously (Halliday et at., 1974 a, b; McCoy
et al., 1980); this extract was used in LAI at a
final concentration of 1/20, which gave
optimal reactivity (Koppi & Halliday, 1981).
Peptide.-Synthetic EAE peptide was
purchased from Peninsula Laboratories,
Inc., San Carlos, Calif., and from Beckman
Instruments, Inc., Palo Alto, Calif., USA. It
is a segment of human MBP, located at
amino-acid residues 114-122, and has the
sequence Phe-Ser-Trp-Gly-Ala-Glu-Gly-Gln-
Arg.
Peritoneal cells (PC).-The mouse cells used
for in vitro assays were obtained from the
peritoneal cavity as described by Yong &
Halliday (1982).
In vitro techniques.-The 3 methods used
for assessing cell-mediated immunity (CMI)
were direct haemacytometer LAI (Halliday &
Miller, 1972; McCoy et al., 1980; Koppi &
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Halliday, 1981), indirect ERA (Morrison &
Halliday, 1980) and direct MMI (McCoy
et al., 1977). In the LAI assay, PC were
incubated for 1 h with and without the re-
quired antigen, and adherences of cells in
these test and control mixtures were de-
termined. The LAI was calculated as the
mean % adherence without antigen minus the
mean % adherence with antigen. In the ERA
assay, PC were incubated for 3-5 h with and
without antigen; supernatants were collected
and antigen was added at the appropriate
level to the control, before storing at -50°C.
The test and control supernatants were then
tested for their augmenting effect on E-
rosette formation by normal human mononu-
clear cells and SRBC; the ERA value was
calculated as the mean % rosettes for the
stimulated supernatant minus the mean %
rosettes for the control supernatant. In the
MMI assay, PC in agarose microdroplets
were incubated with and without antigen for
18 h in micro-wells. The migration patterns
were then quantitated by projecting through
a microscope on to drawing paper, and using a
planimeter to estimate the magnified mi-
gration areas (Yong & Halliday, 1982). The
migration index was the ratio of mean
migration area of PC with antigen to the
mean migration area without antigen.
Statistical determinations of LAI, ERA
and MMI were made by t test comparing
mean % adherence, mean % rosettes and
mean migration area, respectively, for cells
with and without antigen.
Delayed-type hypersensitivity (DTH).
Reactions in mice were elicited by injecting
10 ,ul of saline containing 40 ,ug of EAE
peptide in one footpad and 10 ,1 of saline
alone in the other (control). Measurements of
footpad thickness, before and 24 h after in-
jection, were made with a dial micrometer.
Each foot was removed after killing the mice,
fixed in 10% formalin, decalcified, and
sections were cut, stained with haematoxylin
and eosin, and examined for lymphocytic
infiltration characteristic of DTH.
RESULTS
LAI reactivity of tumour-bearing mice
with EAE peptide
Tumour-bearing mice, known from
previous work (Halliday et al., 1974b;
Koppi & Halliday, 1981) to have PC
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FIGURE. EAE peptide dose-response curves
(semi-log plot) in the LAI assay with
murine PC. * * and 0- -0, mice
bearing MCA-2 tumours in 2 different
experiments; *-*- , mice multiply
infected with N. dubius; A- -
normal mice. * significant LAI.
specifically reactive with tumour extract,
were tested in LAI reactions with a
range of concentrations of EAE peptide
to establish the dose-response character-
istics. The Figure shows the results for 2
esperiments with MCA-2 tumour-bearing
mice (12 days after transplantation).
Over the range of peptide concentrations
80-5000 ng/ml, tumour-bearing PC ex-
hibited increasing LAI up to an optimum
at 640 ng/ml, after which inhibition
gradually decreased. The maximum LAI
values were 14-6 and 17-1 at the optimum,
but significant reactivity between 160 and
2500 ng/ml was obtained. The highest
and lowest levels of antigen induced no
significant LAI.
Normal mice, and mice multiply in-
fectedwithN.dubius, showednosignificant
LAI at any peptide concentration (Figure).
Development of reactivity during tumour
growth
The MCA-2 tumour was transplanted
into 27 mice, and PCs were harvested
from groups of 3-5 animals at different
stages of tumour growth. These cells
were then tested in LAI with optimal
concentrations of tumour extract and
EAE peptide. As mean tumour diameter
-
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Mean EAE
tumour tumour peptide
diameter extract (640
(mm) (1/20) ng/ml)
0*5 3-4 3-2
1-8 1-0 4-8
3-3 11 9* 10 0*
6-9 14-5** 12.1*
10*3 15-8** 14-8**
14*8 19*6** 16.3**
15-3 19*9** 20.2**
t Statistical significance of differences between
control and testadherences indicated thus: *P < 0-01;
**p < 0-001;
gradually increased, significant reactivity
with both antigens appeared 5 days
after tumour inoculation, and continued
to increase until the experiment was
terminated (Table I).
Comparisons between LAI, ERA and MMI
PCs from 3 groups of tumour-bearing
mice 12 days after transplantation were
exposed to a series of concentrations
of EAE peptide (as before) and reactivity
was assessed by LAI, ERA and MMI
assays. The results in Table II show a
direct correlation between all tests: the
TABLE 1I.-Effect of EAE peptide concen-
tration on LAI, ERA and MMI
activities ofPCfrom mice bearing MCA-2
tumour
Concentration
of EAE (ng/ml)
5
10
20
40
80
160
320
640
1250
2500
5000
LAI
NDt
ND
ND
ND
6 0
11.6*
12 4*
17 1***
16 9**
11.0*
2 7
ERA
ND
ND
ND
ND
-3.7
6 8**
5.8*
5.4*
5.2*
1*8
2 4
MMI
index
0.95
0 98
0.78*
0.78*
0.75*
0.75*
0.78*
0-61***
0 60***
0.64**
0 84
t not done.
*P<0.05; **P<0 01; ***P<0001.
optimal concentrations of antigen were
about the same, and reactivity was absent
at both low and high concentrations.
The MMI assay appeared to be the most
sensitive, in that significant reaction
occurred at peptide levels well below
those giving detectable LAI and ERA.
Normal PC had no significant reactivity
with EAE peptide in any assay.
DTH withpeptide
In order to demonstrate recognition
of the EAE peptide in vivo, tumour-
bearing mice and similar mice after
tumour excision were injected in the left
hind footpads with peptide solution in
saline. Control injections of saline alone
were made into the right hind footpad,
and an age-matched control group of
normal mice was similarly treated. The
results of measurements of footpad swell-
ing after 24 h are given in Table III.
Animals currently or previously exposed
to tumour gave small but significant
reactions to the peptide which were not
found with normal mice. In another
experiment, using a smaller dose of
peptide (20 ,ug), footpad swelling was
found at a similar level with tumour-
bearing mice, but not with mice after
tumour removal (data not shown).
The footpad swellings had the histo-
logical characteristics of DTH, as shown
by lymphocytic infiltration of the affected
tissue of peptide-injected feet compared
with saline-injected controls in the same
animals.
DISCUSSION
In vitro reactions involving a peptide
antigen in cancer have previously been
confined to the MEM test in man (Field
et al., 1971; Shaw et al., 1976) and only
the MEM assay had previously been used
to demonstrate a cross-reaction between
human MBP and murine tumours (Paster-
nak et al., 1976). The results obtained here
with LAI, MMI, ERA and DTH reactions
demonstrate the cell-mediated immune
(CMI) reactivity of tumour-bearing mice
to EAE peptide.
TABLE I.-Kineticsofcell-mediated immune
response in mice transplanted with
MCA-2 tumour, as detected by LAI
against homologous tumour extract and
EAE peptide
LAIt
Time after No. of
transplantation mice in
(days) group
1 3
3 3
5 3
7 4
10 5
12 5
14 4
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TABLE III.-Footpad reactions (DTH) against EAE peptide in normal mice, in tumour-
bearing mice, and in mice after tumour removal
Mice (n) Normal (9)
Injection Saline Peptide§
Mean change in footpad thickness+ 0 3+O 8 06+ 1.0
s.e. (mm x 10-2)
>0 5
Tumour-bearing* (13) Tumour-excisedt(10)
Saline Peptide Saline Peptide
-1*1+1 0 4*4+1*5 0*4+0*4 3-5+1*2
<0*025 <0 05
* 12 days after tumour transplantation.
t Tumour removed 7 days after transplantation and footpad reactions performed 18 days later.
t 40 iLg in 10 ,ul of saline.
Shaw etal. (1976) previously showed that
the reaction of lymphocytes from cancer
patients with MBP, CaBP and other
related proteins was not simply due to
their basic nature. They concluded that
the lymphocytes were sensitized to deter-
minants shared by MBP and CaBP,
and thus responded to these antigens in
the MEM test. All the techniques used
here involve T lymphocytes, and depend
on the presence of receptors on these cells
for particular antigenic determinants.
The reactions are therefore a consequence
of immunological recognition, by tumour-
bearer lymphocytes, of an antigenic deter-
minant on the EAE peptide. Furthermore,
reactivity of murine PC to the peptide
in vitro appeared to be related to sensi-
tization by the tumour, and was not
merely the development of unrelated
CMI, since PC from normal mice or mice
with CMI to N. dubius (Dobson & Owen,
1978) were not reactive. As will be re-
ported in detail in a later paper, positive
CMI to the peptide was found in mice
ofseveral different strains bearing tumours
ofdifferent origins.
Determinations of the dose-response
characteristics for EAE peptide as antigen
in each ofthe invitro murine CMIreactions
showed thatLAI, ERAandMMIpossessed
different sensitivities. The ability of lym-
phocytes to react with lower levels of
antigen in MMI may be related to the
fact that the cells remain in contact with
antigen for longer than in the case of
LAI or ERA. Inhibition of reactivity
by excess antigen was always found and
made the use of optimal concentrations
essential. This has been reported previous-
ly with other antigens in LAI (Holt et al.,
1975; Dunn & Halliday, 1980) and ERA
(Morrison & Halliday, 1980).
DTH reactions detected low but signifi-
cant CMI to EAE peptide in tumour-
bearing mice. This novel demonstration
of tumour-related CMI may be compared
with the DTH reactions elicited in
MBP-sensitized mice using the sensitizing
protein (Linthicum et al., 1979). The
small reactions with peptide may have
been due to the rapid diffusion of the
small molecules from the site. It was
anticipated that the reactions would be
larger after tumour removal, when block-
ing factors would have disappeared (Hal-
liday et al., 1974b), but this was not
found.
The development of anti-tumour CMI
during tumour growth in mice, as indi-
cated by LAIreactivity withEAE peptide,
followed a course similar to that reported
previously with tumour extracts as anti-
gens (Maluish & Halliday, 1975). Immuno-
reactivity increased with tumour growth,
and was readily detectable even with
very large tumours. These characteristics
were observed with PC in LAI; it is
possible that other cell populations tested
by other methods might react differently.
The reactive antigen in the tumour
extract used is not related to EAE
peptide or CaBP, since extracts are specific
for individual tumours (Halliday et al.,
1974b).
MBP is known to be highly conserved
between mammalian species (Guarnieri &
Cohen, 1975). Since MBP nevertheless
shows slight differences in structure in
different species, particularly in the region
p
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producing EAE in guinea-pigs (Hashim,
1978) it might be predicted that CaBP
would be common to different tumours in
the one species, but exhibit slight changes
in amino-acid sequence between species.
The actual structure of the immunogenic
determinant of murine CaBP must resem-
ble the human EAE peptide, but is not
necessarily identical. The conformational
requirements for this determinant could
possibly be explored by testing a range
of synthetic peptides for their activity
in vitro with tumour-bearing mouse PC,
as has been done in vivo for the EAE-
inducing determinant of MBP (Westall,
et al., 1971; Hashim, 1978; Khanarian
et al., 1979).
It should be noted that the EAE
peptide is encephalitogenic for guinea-
pigs but not for rats, which respond to a
different region of MBP (Hashim, 1978).
The relevant region in mice has yet to be
precisely defined, but may be similar to
that in rats (Burgess et al., 1978).
All the in vitro techniques used here
have previously been used to investigate
lymphocyte reactivity to MBP in human
cancer with positive results in most cases
(Flavell & Potter, 1978; Schimke &
Ambrosius, 1981). A curious exception
was found with ERA; a few breast-cancer
patients seemed to be unreactive when
tested with MBP (Hashim, 1978), though
the technique readily detects reactivity
to other antigens specific for tumour type
(Ramey et al., 1979; Maluish et al., 1980).
Further testing of cancer patients using
ERA, with materials related to MBP and
CaBP, seems to be warranted in view of
the simplicity of this technique. Prelimin-
ary studies with blood leucocytes from
human cancer patients have revealed LAI
reactivity to EAE peptide (Maluish &
Halliday, unpublished).
CaBP may be only one of a series of
common cell markers related to malignant
tranformation; another is the p53 protein
found in neoplastic cells of mice and other
species (Jay & Khoury, 1980). The
present identification of an antigenic
determinant ofa murine tumour, immuno-
genic in the tumour host and similar to
a well-characterized peptide, provides
an animal model for the precise definition
of the active core of a common tumour-
associated antigen.
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